Second-line chemotherapy in small cell lung cancer.

[1]  V. Ling,et al.  Mechanism of multidrug resistance. , 1988, Biochimica et biophysica acta.

[2]  P. Corris,et al.  The multidrug resistant phenotype in clinical practice; evaluation of cross resistance to ifosfamide and mesna after VP16-213, doxorubicin and vincristine (VPAV) for small cell lung cancer. , 1988, European journal of cancer & clinical oncology.

[3]  G. Giaccone,et al.  Reinduction chemotherapy in small cell lung cancer. , 1987, European journal of cancer & clinical oncology.

[4]  R. Feld,et al.  Cyclophosphamide, doxorubicin, and vincristine in etoposide- and cisplatin-resistant small cell lung cancer. , 1987, Cancer treatment reports.

[5]  P. Postmus,et al.  Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy. , 1987, European journal of cancer & clinical oncology.

[6]  D. Osoba,et al.  Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  M. Slevin,et al.  High-dose cytarabine in small cell lung cancer. , 1987, Cancer treatment reports.

[8]  R. Holle,et al.  Alternating versus sequential chemotherapy in small cell lung cancer. A randomized german multicenter trial , 1987, Cancer.

[9]  E. Creagan,et al.  Cyclophosphamide, Etoposide, and Infusion Cisplatin in Refractory Small Cell Lung Cancer , 1987, American Journal of Clinical Oncology.

[10]  F. Greco,et al.  Ifosfamide plus N-acetylcysteine in the treatment of small cell and non-small cell carcinoma of the lung: a Southeastern Cancer Study Group Trial. , 1986, Cancer treatment reports.

[11]  P. Bunn,et al.  Etoposide (VP-16) and cisplatin in previously treated small-cell lung cancer: clinical trial and in vitro correlates. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  G. Bodey,et al.  Combination chemotherapy with vindesine and cisplatin for refractory small cell bronchogenic carcinoma. , 1986, Cancer treatment reports.

[13]  F. Greco,et al.  Randomized dose-response evaluation of etoposide in small cell carcinoma of the lung: a Southeastern Cancer Study Group Trial. , 1986, Cancer treatment reports.

[14]  D. Johnson,et al.  Cisplatin and etoposide combination chemotherapy for refractory small cell carcinoma of the lung. , 1985, Cancer treatment reports.

[15]  J. Mann,et al.  Etoposide and cisplatin salvage chemotherapy for small cell lung cancer. , 1985, Cancer treatment reports.

[16]  D. Gandara,et al.  Chemotherapy of small-cell carcinoma of lung: a randomized comparison of alternating and sequential combination chemotherapy programs. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  G. Green,et al.  Mitomycin‐C, etoposide, cisplatin, and hexamethylmelamine (MEPH) as a second‐line regimen in lung cancer , 1984, American journal of clinical oncology.

[18]  H. Hansen,et al.  Cyclic alternating 'non-cross resistant' chemotherapy in the management of small cell anaplastic carcinoma of the lung. , 1984, Cancer Treatment Reviews.

[19]  S. Seeber,et al.  Treatment of recurrent small cell lung carcinoma with vindesine and cisplatin. , 1984, Cancer treatment reports.

[20]  D. Osoba,et al.  VP‐16 alone and in combination with cisplatin in previously treated patients with small cell lung cancer , 1984, Cancer.

[21]  P. Bunn,et al.  Small-cell carcinoma of lung: reinduction therapy after late relapse. , 1983, Annals of internal medicine.

[22]  A. Goldhirsch,et al.  Mitomycin, hexamethylmelamine, and vindesine as second-line treatment for small cell cancer of the lung. , 1982, Cancer treatment reports.

[23]  D. V. Van Echo,et al.  CCNU, vincristine, methotrexate, and procarbazine treatment of relapsed small cell lung carcinoma. , 1982, Cancer treatment reports.

[24]  S. Seeber,et al.  Small-cell bronchogenic carcinoma--primary and relapse therapy with etoposide (VP-16), methotrexate and CCNU. , 1982, Cancer treatment reviews.

[25]  J. Minna,et al.  Combination chemotherapy with vincristine, adriamycin, and procarbazine in previously treated patients with small cell carcinoma. , 1977, Cancer treatment reports.

[26]  A. Ardizzoni,et al.  Cisplatin and etoposide as second-line chemotherapy in patients with small cell lung cancer. , 1988, Cancer investigation.

[27]  L. Vindeløv.  Cell kinetics, tumour heterogeneity and antineoplastic treatment of small cell carcinoma of the lung , 1985 .

[28]  D. Osoba,et al.  Etoposide (VP-16) and cisplatin: an effective treatment for relapse in small-cell lung cancer. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  J H Goldie,et al.  Rationale for the use of alternating non-cross-resistant chemotherapy. , 1982, Cancer treatment reports.

[30]  M. Tempero,et al.  VP-16-213 therapy in patients with small-cell carcinoma of the lung after failure on combination chemotherapy. , 1981, Cancer clinical trials.

[31]  F. Greco,et al.  Phase II studies in resistant small cell lung cancer , 1979 .